Back to top

Essential Steps to Help Patients of Color Control BP

Address these four barriers to help minority patients lower their blood pressure.

Electronic prior authorization technology integrated with practices’ e-prescribing workflow can speed the process. The AMA also advocates other PA reforms.

In trauma settings, physicians often make urgent decisions without knowledge of the patient’s identity, values or history, which can leave a lasting impression on patients and their loved ones.

Medical trainees are in a particularly vulnerable position when it comes to sexual harassment. Stakeholders in medical education discuss ways to protect them.

Gibson KF, Kass DJ.
The “treatment era” for idiopathic pulmonary fibrosis (IPF) in the United States and other countries was inaugurated in November 2014 following the Food and Drug Administration’s (FDA’s) approval of pirfenidone and nintedanib as treatments for IPF. Even the most optimistic pulmonologists may have doubted that such a day would ever arrive, let alone a day when a practicing clinician would have not 1, but 2 medications to treat IPF. The FDA approved pirfenidone and nintedanib on the basis of published studies that showed these therapies slowed the rate of deterioration of forced vital capacity (FVC).
  • AMA Membership
    Join Now
    Become a Member of the AMA and receive practice and career benefits.
  • Patients First
    Take Action
    Join us in putting patients before politics in health care reform.
  • AMA Insurance
    Now Save 35%
    AMA member physicians get a 35% discount on own specialty disability insurance.